Delving into the Latest Updates on Cefbuperazone Sodium with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Cefbuperazone, Cefbuperazone sodium (JP17)

+ [3]

Target

PBPs

Action

inhibitors

Mechanism

PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesDigestive System Disorders+ [5]

Active Indication

Bacterial InfectionsBronchiectasisBronchitis, Chronic+ [15]

Inactive Indication

Hepatobiliary infectionLower Respiratory Tract InfectionsUrinary Tract Infections

Originator Organization-

Active Organization

Haikou Pharmaceutical Factory Co., Ltd

Chongqing Tiandi Medicine Co., Ltd.

Yuekang Pharmaceutical Group Co., Ltd.

+ [1]

Inactive Organization

Guilin Pharmaceutical Group Co., Ltd.

Hainan General Sanyang Pharmaceutical Co. Ltd.

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC22H29N9O9S2

InChIKeySMSRCGPDNDCXFR-CYWZMYCQSA-N

CAS Registry76610-84-9

View All Structures (2)

考察健康志愿者单次或多次静脉滴注由海南通用三洋药业有限公司开发的注射用头孢拉宗钠后血药浓度经时变化过程，估算相应的药代动力学参数，评价头孢拉宗在人体内的药代动力学特征，为II期临床试验方案制定提供试验依据，为临床用药的给药剂量提供依据。

[Translation]

To investigate the time-dependent changes in blood concentration of cefoperazone sodium for injection developed by Hainan General Sanyo Pharmaceutical Co., Ltd. in healthy volunteers after single or multiple intravenous infusions, estimate the corresponding pharmacokinetic parameters, evaluate the pharmacokinetic characteristics of cefoperazone in humans, provide experimental basis for the formulation of Phase II clinical trial plans, and provide basis for clinical drug dosage.

Start Date27 Aug 2015

Sponsor / Collaborator

Hainan General Sanyang Pharmaceutical Co. Ltd.

CTR20150130

/ CompletedPhase 3

注射用头孢拉宗钠治疗中、重度呼吸和泌尿系统急性细菌感染的随机、单盲、阳性药平行对照、多中心临床试验

[Translation] A randomized, single-blind, positive-drug parallel-controlled, multicenter clinical trial of cefuroxime sodium for injection in the treatment of moderate to severe acute bacterial infections of the respiratory and urinary systems

以注射用头孢美唑钠为对照，评价注射用头孢拉宗钠治疗中、重度呼吸和泌尿系统急性细菌感染的有效性和安全性。

[Translation]

To evaluate the efficacy and safety of cefoperazone sodium for injection in the treatment of moderate to severe acute bacterial infections of the respiratory and urinary systems, using ceftriaxone sodium for injection as a control.

Start Date04 Feb 2015

Sponsor / Collaborator

Hainan General Sanyang Pharmaceutical Co. Ltd.

100 Clinical Results associated with Cefbuperazone Sodium

Login to view more data

100 Translational Medicine associated with Cefbuperazone Sodium

Login to view more data

100 Patents (Medical) associated with Cefbuperazone Sodium

Login to view more data

220

Literatures (Medical) associated with Cefbuperazone Sodium

01 Sep 2021·World Allergy Organization Journal

Risk factors of beta-lactam anaphylaxis in Korea: A 6-year multicenter retrospective adult case-control study

Article

Author: Nam, Young-Hee ; Park, So-Young ; Park, Chan Sun ; Jung, Jae-Woo ; Kang, Hye-Ryun ; Park, Hye-Kyung ; Park, Hye Jung ; Kang, Dong-Yoon ; Kim, Sujeong ; Yang, Min-Suk

BACKGROUNDBeta-lactams (BLs) are commonly used antibiotics and leading causative agents of drug-induced anaphylaxis. Few studies on the culprit drugs and risk factors of BL-induced anaphylaxis are available. Our goal was to evaluate the culprit drugs and compare the risk factors in patients with BL-induced anaphylaxis to matched tolerant controls in a hospital setting.METHODSWe retrospectively enrolled all patients who developed anaphylaxis from intravenous BL during hospitalization from 9 Korean hospitals. We compared clinical parameters between patients with BL-induced anaphylaxis and 4-fold BL-tolerant controls matched by age, sex, BL use, and the purpose of BL administration.RESULTSSeventy-four cases of BL-induced anaphylaxis and 296 BL-tolerant controls were enrolled. Cephalosporin accounted for 77% of total BL-induced anaphylaxis, and the top derivatives were ceftriaxone (23.0%), cefazedone (10.8%), and cefbuperazone (9.5%). Among penicillin derivatives, piperacillin (16.2%) was the most common, followed by ampicillin (2.7%). History of drug allergy (odds ratio [OR], 19.91; 95% confidence interval [CI] 5.33-74.44), previous exposure to the causative BL (OR, 7.71; 95% CI, 1.62-36.76), and concurrent administration of angiotensin-converting enzyme inhibitors (ACEIs) (OR, 5.97; 95% CI, 1.28-27.91) were independent risk factors associated with BL-induced anaphylaxis. Food allergy (OR, 13.93; 95% CI 1.31-148.9) and previous exposure to BL (OR, 6.59; 95% CI, 1.30-33.31) were identified as risk factors for cephalosporin-induced anaphylaxis.CONCLUSIONSTo prevent BL-induced anaphylaxis, attention should be paid to histories of drug or food allergy, previous exposure to BLs, and ACEI use. The risk factors and clinical outcomes might vary according to the BL classes.

01 Jan 2021·Computational and Structural Biotechnology JournalQ3 · BIOLOGY

Docking-generated multiple ligand poses for bootstrapping bioactivity classifying Machine Learning: Repurposing covalent inhibitors for COVID-19-related TMPRSS2 as case study

Q3 · BIOLOGY

ArticleOA

Author: Hatmal, Ma'mon M ; Taha, Mutasem ; Abuyaman, Omar

In the present work we introduce the use of multiple docked poses for bootstrapping machine learning-based QSAR modelling. Ligand-receptor contact fingerprints are implemented as descriptor variables. We implemented this method for the discovery of potential inhibitors of the serine protease enzyme TMPRSS2 involved the infectivity of coronaviruses. Several machine learners were scanned, however, Xgboost, support vector machines (SVM) and random forests (RF) were the best with testing set accuracies reaching 90%. Three potential hits were identified upon using the method to scan known untested FDA approved drugs against TMPRSS2. Subsequent molecular dynamics simulation and covalent docking supported the results of the new computational approach.

01 Sep 2018·AllergyQ1 · MEDICINE

Incidence of cephalosporin‐induced anaphylaxis and clinical efficacy of screening intradermal tests with cephalosporins: A large multicenter retrospective cohort study

Q1 · MEDICINE

Article

Author: Ahn, Y.‐M. ; Park, H. J. ; Jang, G. C. ; Koo, S.‐M. ; Yang, H.‐J. ; Nam, Y.‐H. ; Seo, B. ; Kim, S. ; Park, J.‐W. ; Park, K. H. ; Park, S.‐Y. ; Kim, M.‐Y. ; Jung, J.‐W. ; Kim, T.‐B. ; Kang, H.‐R. ; Kang, D.Y. ; Yang, M.‐S.

AbstractBackgroundFew studies have investigated the incidence of anaphylaxis induced by individual or structurally similar cephalosporins. The aims of the study were to assess the incidence of cephalosporin‐induced anaphylaxis and evaluate the clinical efficacy of screening skin tests.MethodsIn this retrospective cohort study, we obtained information on total cephalosporin use and cephalosporin‐induced anaphylaxis in intravenous cephalosporin recipients in 12 general hospitals between 2013 and 2015. Cephalosporins were divided into 4 groups according to similar side‐chain structures. The incidence of cephalosporin‐induced anaphylaxis was assessed for each cephalosporin, cephalosporin generation, and side‐chain group. To verify the efficacy of screening intradermal tests (IDT) with cephalosporin, the 12 hospitals were assigned to the intervention or control group depending on whether they performed screening IDT before the administration of cephalosporins.ResultsWe identified 76 cases of cephalosporin‐induced anaphylaxis with 1 123 345 exposures to intravenous cephalosporins (6.8 per 100 000 exposures), and the incidence of fatal anaphylaxis by cephalosporin was 0.1 cases per 100 000 exposures. The highest incidences of anaphylaxis occurred in the ceftizoxime (13.0 cases per 100 000 exposures) and side‐chain group 1 (cefepime, cefotaxime, ceftizoxime, ceftriaxone, and cefuroxime; 9.3 per 100 000). There was no case of anaphylaxis induced by cefoxitin, cefmetazole, cefminox, and cefotiam. The clinical effectiveness of routine screening IDT was not significant (P = .06).ConclusionsThe incidence of cephalosporin‐induced anaphylaxis differed according to individual drugs and side‐chain structure. Screening IDT showed no clinical efficacy at a population level.

100 Deals associated with Cefbuperazone Sodium

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01736	Cefbuperazone Sodium	J01DC13	DB13638

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	-	-	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Lower Respiratory Tract Infections	Phase 2	China	Hainan General Sanyang Pharmaceutical Co. Ltd.	04 Feb 2015
Urinary Tract Infections	Phase 2	China	Hainan General Sanyang Pharmaceutical Co. Ltd.	04 Feb 2015
Cholangitis	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Cholecystitis	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Cystitis	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Empyema	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Endocarditis	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Peritonitis	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Pneumonia	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014
Pyelonephritis	Phase 2	China	Guilin Pharmaceutical Group Co., Ltd.	02 Apr 2014